On October 20, 2026 Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") reported that it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for patients with second-line relapsed or refractory acute myeloid leukemia (AML). The discussion highlights the completion of enrollment in Part A, encouraging interim efficacy results, Annamycin’s potential to address treatment resistance and cardiac safety concerns associated with conventional anthracyclines, and the anticipated full 90-patient Part A data readout in the first quarter of 2027. Mr. Klemp also outlines the next steps toward the pivotal Part B expansion and the broader potential for Annamycin across AML and other cancers treated with anthracyclines.
(Press release, Moleculin, OCT 20, 2026, View Source [SID1234673606])